Mode
Text Size
Log in / Sign up

2024 ACR guidelines for lupus nephritis require caution in pediatric practice due to adult-derived evidenceAdult Lupus Kidney Guidelines May Not Fit Children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that 2024 ACR guidelines for lupus nephritis rely on adult-derived evidence for steroid dosing and long-term safety.

This guideline review evaluates the 2024 ACR guidelines for lupus nephritis, specifically focusing on their applicability to pediatric populations. The review notes that while the fundamental principles of lupus nephritis management are largely age-agnostic, many quantitative recommendations are not. Specifically, the guidelines' recommendations regarding glucocorticoid dosing, long-term treatment exposure, and developmental consequences are not tailored for children.

The authors highlight that the evidence base for these guidelines is largely adult-derived. Consequently, there is limited pediatric evidence regarding glucocorticoid dosing, long-term biologic safety, fertility, and growth. These factors are critical considerations when managing children with lupus nephritis.

Clinicians should exercise caution when applying adult-derived guidelines to pediatric patients. The review identifies a significant need for dedicated pediatric trials to establish evidence-based protocols for steroid dosing and long-term biologic safety in children. Practice relevance is centered on identifying these gaps where adult-derived guidelines may not translate directly to pediatric clinical needs.

How this fits prior evidence

This guideline addresses a gap in pediatric-specific management by highlighting that while 2024 ACR guidelines are applicable to both adults and children, the evidence base remains largely adult-derived. It complements existing knowledge on lupus nephritis, such as the role of BAFF and APRIL signaling pathways in autoantibody production and the use of rituximab-based therapy for renal response, by emphasizing the need for specific pediatric data regarding glucocorticoid dosing and long-term biologic safety.

A new review looks at how well the 2024 American College of Rheumatology guidelines for lupus nephritis apply to children. Lupus nephritis is a kidney problem that can affect people with lupus. The guidelines are the first to say they apply to both adults and children. But the review notes that the evidence behind them comes mostly from studies in adults.

The review found that the basic principles of managing lupus nephritis are largely the same for all ages. However, many specific recommendations are not. These include how much steroid medicine to give, how long to use treatments, and how treatments might affect a child's growth and development.

The authors point out that pediatric evidence is limited for several important areas. These include steroid dosing, the long-term safety of biologic drugs, fertility, and growth. The review does not report any new safety data or numbers.

The main message is that doctors should be careful when using adult-based guidelines for children. More research is needed specifically in children. Parents and caregivers should talk with their child's doctor about how these guidelines apply to their situation.

What this means for you:
Lupus kidney guidelines now cover children, but most evidence is from adults, so caution is needed.

Common questions

Do the 2024 ACR lupus nephritis guidelines apply to children?

Yes, the 2024 guidelines are the first to explicitly state they apply to both adults and children. However, the review notes that the evidence behind them is largely from adult studies. So while the guidelines cover children, some specific recommendations may not fit pediatric patients well.

What parts of the guidelines are uncertain for children?

The review says pediatric evidence is limited for glucocorticoid dosing, long-term biologic safety, fertility, and growth. These are areas where adult-derived recommendations may need extra caution when used in children. More research in children is needed.

Are the basic principles of lupus nephritis care the same for children and adults?

The review found that fundamental principles of lupus nephritis management are largely age-agnostic. That means the general approach is similar. But many quantitative recommendations, like steroid doses and long-term treatment exposure, are not the same for children.

What should parents do with this information?

This review highlights that children may need different care than adults for lupus nephritis. Parents should talk with their child's doctor about how the guidelines apply to their child. Decisions about treatment should always be made with a healthcare professional.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedOct 2026
View Original Abstract ↓
Lupus nephritis (LN) is more common and often more aggressive in children than in adults, yet most randomized trials informing current LN management have enrolled adults. The 2024 American College of Rheumatology (ACR) guideline is the first ACR guideline on lupus nephritis to explicitly state that its recommendations apply to both adults and children, although its evidence base remains largely adult-derived. This review uses the 2024 ACR guideline as an organizing framework, cross-referenced with the 2024 KDIGO and 2025 EULAR recommendations, to examine which aspects of LN management translate effectively to pediatric practice and which require caution. We review the diagnostic pathway, including screening, kidney biopsy, and ISN/RPS classification, as well as therapeutic strategies, including the shift from sequential dual therapy to upfront triple therapy, response targets, class-specific treatment, and selection between belimumab and calcineurin inhibitors. We then examine areas where pediatric evidence remains limited, particularly glucocorticoid dosing, long-term biologic safety, fertility and growth, and transition to adult care. While the fundamental principles of LN management are largely age-agnostic, many quantitative recommendations are not. Steroid dosing, long-term treatment exposure, and developmental consequences remain important pediatric-specific considerations that current guidelines cannot fully address. We conclude by highlighting the pediatric evidence available to date and the need for dedicated pediatric trials to replace adult-derived extrapolation with child-specific evidence.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.